Abstract:Given the prevalent advancements in DNA- and RNA-based PROTACs, there remains a significant need for the exploration and expansion of more specific DNA-based tools, thus broadening the scope and repertoire of DNA-based PROTACs. Unlike conventional A- or B-form DNA, Z-form DNA is a configuration that exclusively manifests itself under specific stress conditions and with specific target sequences, which can be recognized by specific reader proteins, such as ADAR1 or ZBP1, to exert downstream biological functions. The core of our innovation lies in the strategic engagement of Z-form DNA with ADAR1 and its degradation is achieved by leveraging a VHL ligand conjugated to Z-form DNA to recruit the E3 ligase. This ingenious construct engendered a series of Z-PROTACs, which we utilized to selectively degrade the Z-DNA-binding protein ADAR1, a molecule that is frequently overexpressed in cancer cells. This meticulously orchestrated approach triggers a cascade of PANoptotic events, notably encompassing apoptosis and necroptosis, by mitigating the blocking effect of ADAR1 on ZBP1, particularly in cancer cells compared with normal cells. Moreover, the Z-PROTAC design exhibits a pronounced predilection for ADAR1, as opposed to other Z-DNA readers, such as ZBP1. As such, Z-PROTAC likely elicits a positive immunological response, subsequently leading to a synergistic augmentation of cancer cell death. In summary, the Z-DNA-based PROTAC (Z-PROTAC) approach introduces a modality generated by the conformational change from B- to Z-form DNA, which harnesses the structural specificity intrinsic to potentiate a selective degradation strategy. This methodology is an inspiring conduit for the advancement of PROTAC-based therapeutic modalities, underscoring its potential for selectivity within the therapeutic landscape of PROTACs to target undruggable proteins.

ZIF-90-loaded DNAzyme-responsive PROTAC for the Self-Powered Degradation of NF-κB

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC

Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG (Adv. Sci. 20/2021)

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

DNA framework-engineered chimeras platform enables selectively targeted protein degradation

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

MicroRNA‐Triggered Programmable DNA‐Encoded Pre‐PROTACs for Cell‐Selective and Controlled Protein Degradation

ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer.

Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1.

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin

Targeted Degradation of Transcription Factors by TRAFTACs: Transcription Factor Targeting Chimeras

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Protocol for constructing tumor-targeting ANM-PROTACs for degradation of transcription factors

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16